Read news on Novo Nordisk with our app.
Read more in the app
Novo Nordisk chair and directors quit after boardroom rift
Novo Nordisk's Canadian Mistake
Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee
Novo Nordisk Loses Canadian Patent Protection For Blockbuster Diabetes Drug Over Unpaid $450 Fee
SAP leapfrogs Novo Nordisk to become Europe’s most valuable company
Novo Nordisk, Sanofi Face South Africa Insulin Antitrust Probe
Novo Nordisk Takes $820 Million Charge on Failed Heart Drug
FTC challenges 'junk' patents held by 10 drugmakers, incl Novo Nordisk's Ozempic
